A Lymphatic-Absorbed Multi-Targeted Kinase Inhibitor for Myelofibrosis Therapy

Researchers demonstrated selectivity and therapeutic efficacy of a potent orally bioavailable multi-functional kinase inhibitor through reduction of downstream kinase activation, amelioration of disease phenotypes, and improved survival in animal models of myelofibrosis.